OBJECTIVES: Cervical cancer is one of the most common gynecological malignancies worldwide, and its association with the AMP-activated protein kinase (AMPK) is still unknown. We aimed to investigate the clinical correlation between AMPK expression and cervical cancer. METHODS: The expression of AMPKα1, AMPKα2 and phosphorylated AMPKα (p-AMPKα) was determined immunohistochemically in 524 formalin-fixed, paraffin-embedded malignant and premalignant cervical tissues. Subsequently, associations with clinicopathological characteristics and patient survival were assessed. RESULTS: AMPKα2 expression was observed in the cytoplasm and nucleus, while expression of AMPKα1 and p-AMPKα was mainly observed in the cytoplasm. p-AMPKα expression increased during the normal-to-tumor transition of cervical carcinoma (p < 0.001), but, once cancer developed, the expression of AMPKα2 and p-AMPKα decreased in large-sized tumors when compared to smaller tumors (36 vs. 68%, p = 0.004 and 39 vs. 64%, p = 0.029, respectively). Notably, AMPKα2 expression was significantly associated with better disease-free survival (HR 0.29, 95% CI 0.10-0.86, p = 0.026). CONCLUSION: The AMPKα2 isoform showed potential as a favorable prognostic marker in cervical cancer. Therefore, additional studies are necessary to further clarify the complex contribution of AMPK isoforms and of phosphorylation status to cervical cancer progression and prognosis.
OBJECTIVES:Cervical cancer is one of the most common gynecological malignancies worldwide, and its association with the AMP-activated protein kinase (AMPK) is still unknown. We aimed to investigate the clinical correlation between AMPK expression and cervical cancer. METHODS: The expression of AMPKα1, AMPKα2 and phosphorylated AMPKα (p-AMPKα) was determined immunohistochemically in 524 formalin-fixed, paraffin-embedded malignant and premalignant cervical tissues. Subsequently, associations with clinicopathological characteristics and patient survival were assessed. RESULTS:AMPKα2 expression was observed in the cytoplasm and nucleus, while expression of AMPKα1 and p-AMPKα was mainly observed in the cytoplasm. p-AMPKα expression increased during the normal-to-tumor transition of cervical carcinoma (p < 0.001), but, once cancer developed, the expression of AMPKα2 and p-AMPKα decreased in large-sized tumors when compared to smaller tumors (36 vs. 68%, p = 0.004 and 39 vs. 64%, p = 0.029, respectively). Notably, AMPKα2 expression was significantly associated with better disease-free survival (HR 0.29, 95% CI 0.10-0.86, p = 0.026). CONCLUSION: The AMPKα2 isoform showed potential as a favorable prognostic marker in cervical cancer. Therefore, additional studies are necessary to further clarify the complex contribution of AMPK isoforms and of phosphorylation status to cervical cancer progression and prognosis.
Authors: Hyeon Ung Park; Simeng Suy; Malika Danner; Vernon Dailey; Ying Zhang; Henghong Li; Daniel R Hyduke; Brian T Collins; Gregory Gagnon; Bhaskar Kallakury; Deepak Kumar; Milton L Brown; Albert Fornace; Anatoly Dritschilo; Sean P Collins Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261
Authors: Dana M Gwinn; David B Shackelford; Daniel F Egan; Maria M Mihaylova; Annabelle Mery; Debbie S Vasquez; Benjamin E Turk; Reuben J Shaw Journal: Mol Cell Date: 2008-04-25 Impact factor: 17.970
Authors: D Stapleton; K I Mitchelhill; G Gao; J Widmer; B J Michell; T Teh; C M House; C S Fernandez; T Cox; L A Witters; B E Kemp Journal: J Biol Chem Date: 1996-01-12 Impact factor: 5.157
Authors: Mingo Ming Ho Yung; David Wai Chan; Vincent Wing Sun Liu; Kwok-Ming Yao; Hextan Yuen-Sheung Ngan Journal: BMC Cancer Date: 2013-07-03 Impact factor: 4.430
Authors: Chel Hun Choi; Joon-Yong Chung; Eun Joo Chung; John D Sears; Jeong-Won Lee; Duk-Soo Bae; Stephen M Hewitt Journal: BMC Cancer Date: 2016-07-11 Impact factor: 4.430
Authors: Orieta Celiku; Anita Tandle; Joon-Yong Chung; Stephen M Hewitt; Kevin Camphausen; Uma Shankavaram Journal: BMC Med Genomics Date: 2017-03-09 Impact factor: 3.063
Authors: Mijung Kwon; Jae-Hoon Kim; Yevangelina Rybak; Alex Luna; Chel Hun Choi; Joon-Yong Chung; Stephen M Hewitt; Asha Adem; Elizabeth Tubridy; Juan Lin; Steven K Libutti Journal: Oncotarget Date: 2016-11-22